Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.
about
Osteopontin-A Master Regulator of Epithelial-Mesenchymal TransitionManagement of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survivalRole of osteopontin in systemic lupus erythematosusMechanisms linking excess adiposity and carcinogenesis promotionOsteopontin: At the cross-roads of myocyte survival and myocardial functionEffects of canonical NF-κB signaling pathway on the proliferation and odonto/osteogenic differentiation of human stem cells from apical papilla.Measuring levels of osteopontin as potential biomarker for hepatocellular carcinoma in Syrian patients.Osteopontin knockdown suppresses the growth and angiogenesis of colon cancer cells.Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies.Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma.Quantification of the concentration gradient of biomarkers between ovarian carcinoma interstitial fluid and blood.Osteopontin Expression in Patients with HepatolithAssociation between promoter polymorphisms of OPN gene and cancer risk: a meta-analysis.Low expression of GNAI3 predicts poor prognosis in patients with HCC.Osteopontin splice variants differentially exert clinicopathological features and biological functions in gastric cancerMatricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localizationMechanism of hepatitis C virus (HCV)-induced osteopontin and its role in epithelial to mesenchymal transition of hepatocytesPrognostic significance of osteopontin expression in gastric cancer: a meta-analysis.Osteopontin stimulates apoptosis in adult cardiac myocytes via the involvement of CD44 receptors, mitochondrial death pathway, and endoplasmic reticulum stress.NF‑κB inhibition is associated with OPN/MMP‑9 downregulation in cutaneous melanoma.RAN GTPase and Osteopontin in Pancreatic Cancer.Circulating markers for prognosis of hepatocellular carcinoma.Osteopontin as a therapeutic target for cancer.Targeting osteopontin, the silent partner of Na+/H+ exchanger isoform 1 in cardiac remodeling.Osteopontin -- a promising biomarker for cancer therapy.The role of osteopontin expression in melanoma progression.Sildenafil, a Phosphodiesterase Type 5 Inhibitor, Downregulates Osteopontin in Human Peripheral Blood Mononuclear Cells.Multiplexed cancer biomarker detection using chip-integrated silicon photonic sensor arrays.OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLCAssociation of osteopontin expression with the prognosis of glioma patient: a meta-analysis.Osteopontin as a marker for response to pegylated interferon Alpha-2b treatment in Chronic HCV Saudi patients.microRNAs and Endometrial Pathophysiology.SIRT1 overexpression protects non-small cell lung cancer cells against osteopontin-induced epithelial-mesenchymal transition by suppressing NF-κB signaling.Osteopontin regulates HCV replication and assembly via interaction with HCV proteins and lipid droplets and by binding to receptors, αVβ3 and CD44.Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer.
P2860
Q26749570-E807803C-4CB8-4614-9B76-FBC7E9094B38Q26853543-5D5CB068-2CDA-4331-A0F9-79A0C5CD441AQ27006644-34454DA9-1A7C-4B99-BD3F-B6F6AB09CA54Q27022929-453A35A0-8D4D-44BF-8E48-A467E1057E30Q28248833-314B601B-1610-45BE-88E0-7FB0F0CB7277Q33597930-DA086C3D-4D1D-4F68-8204-77CB11BDE7AFQ33867375-CF5B41E6-BD33-4DC2-9C10-2C54598BDC04Q34036685-8EAD3756-596D-4F15-AD65-5E7014575672Q34039967-CF34129D-ECFA-403C-B27F-ED6DF638284AQ34775377-EDF0712E-7E91-40E7-8E2A-C7E2A5AB9F1EQ36250701-D28CED25-DAC8-459B-877B-FF541356D312Q36408616-AA6C0DBF-04FF-4FC3-8BB1-AAA37EE2578DQ36425495-CC730EBD-BEDE-44A9-B24E-011B4BDE17A4Q36493158-249E67AD-49B1-4129-9C1F-FC95D277C957Q36503987-CC008088-0DAB-419B-BD9C-F53CE3BE76CEQ36578825-94EF8F19-3789-4B8B-B29B-B7B55FC40B56Q37415614-8CAA569A-9BFD-4F6E-9D86-1287A25AF2E3Q37688419-A4666917-0964-497F-964C-550C1D8455A2Q37707655-83406DBA-6591-41F2-ACF3-8F2B410A312BQ37707767-097B4B4B-7EF3-4339-86C5-C261D3DCBCB5Q37707966-1E6F7CE8-8500-48F6-9E81-83D22C93661FQ38103946-97B308AC-1DF0-4D1A-90BB-03A58FFA6FDEQ38217758-30D94F7A-30F4-4A35-948D-02DE9E5A11C5Q38354012-8680BCB6-8213-47F2-990D-3C4373F3B260Q38619009-9DA09DEF-7257-46D4-9CE0-A4075939C0DBQ40973252-B04EB1FD-FEA7-44D9-A0B2-791D5CC91D0FQ41020428-3D03002E-0200-4A3C-83EE-B29FB6CC8190Q41504856-370C461E-7AE0-4DBD-B837-E96C80529182Q42200175-4830A71A-EC83-40C8-9F12-18FEC4515D9EQ45737032-DEF26419-2386-4E6C-BD01-7B8041995F8FQ46606704-79361CEF-D75A-42D1-90DA-343E8492D2B0Q50544691-C6E36C8C-DE23-4305-833B-F5D6371DE35BQ51734190-398980BC-277F-4052-A081-67EA0AE3DEDBQ52718495-5F188C53-88E7-44A7-ADD7-90ADE8440CD8Q53550064-E06450A2-405B-475D-97B0-DEEFFCD01EDA
P2860
Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.
@en
Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.
@nl
type
label
Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.
@en
Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.
@nl
prefLabel
Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.
@en
Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.
@nl
P2093
P2860
P356
P1476
Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.
@en
P2093
Dong-Xing Cao
Ester Khin
Guo-Hao Wu
Nikki P Lee
Xiao-Ou Jiang
Yick Liang Lum
Zhi-Jie Li
P2860
P304
P356
10.3748/WJG.V18.I30.3923
P407
P50
P577
2012-08-01T00:00:00Z